Company description

Cogent Biosciences, Inc. (CGNT) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of genetically driven diseases. The company's mission is to improve the lives of patients by targeting the underlying genetic causes of rare disorders. Led by a team of seasoned industry veterans, Cogent utilizes precision medicine and cutting-edge technologies to identify and develop potential treatments for debilitating conditions such as precision oncology, precision rheumatology, and precision immunology. The company prides itself on its strong pipeline of innovative product candidates, including its lead candidate, CG-806, which is being evaluated in clinical trials for the treatment of chronic lymphocytic leukemia and other B-cell malignancies. Additionally, Cogent has a robust research and development program, with collaborations and partnerships with leading academic institutions and biopharmaceutical companies. With a commitment to scientific excellence and a focus on addressing unmet medical needs, Cogent Biosciences is poised for growth and potential success in the rapidly advancing field of precision medicine.